Communiqués Cerenome, Inc.

Actions

CNSY

US72941H8060

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
1,600 ^USD	-10,11 %		-19,60 %	-87,51 %

30/09	Transcript : Cerenome, Inc. - Special Call
14/08	Cerenome, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Communiqués

30/09	Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings	AQ
25/09	Cerenome to Hold CNSide® Business Update Call on September 30, 2026	AQ
22/09	Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives	AQ
16/09	Cerenome Appoints Samantha Fowlkes as Vice President and Head of Commercial Sales, CNSide Diagnostics Division	AQ
10/09	Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment	AQ
20/08	Cerenome Highlights Presentations at the 2026 SNO/ASCO CNS Metastases Conference Demonstrating Progress in Both Therapeutics and Diagnostics Business Lines	AQ
14/08	Cerenome: Q2 Earnings Snapshot	AQ
14/08	Cerenome Reports Second Quarter 2026 Financial Results and Business Update	AQ
13/08	Cerenome Secures In-Network Agreement with Health Care Service Corporation, Expanding CNSide® Contracted Coverage to Over 150 Million Covered Lives	AQ
06/08	Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform	AQ
03/08	Plus Therapeutics, Inc. - Cerenome Launches as an Integrated CNS Oncology Company	AQ
31/07	Cerenome Launches as an Integrated CNS Oncology Company	AQ
28/07	Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference	AQ
21/07	Plus Therapeutics Secures Regional Coverage Agreement with Medical Mutual for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer	AQ
16/07	Plus Therapeutics and Genomic Testing Cooperative Partner to Integrate Next-Generation Sequencing Into the CNSide® CSF Assay Platform	AQ
14/07	Plus Therapeutics Highlights NCCN CNS Cancers Guidelines Update and Reinforces Clinical Role of CNSide® in Leptomeningeal Metastases Monitoring	AQ
30/06	Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding	AQ
26/06	Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide Cerebrospinal Fluid Assay for Metastatic CNS Cancer	AQ
25/06	Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer	AQ
23/06	Plus Therapeutics to Provide Business Update Call on June 30, 2026	AQ
05/06	Plus Therapeutics Announces CAP Accreditation of CNSide Diagnostics Clinical Laboratory	AQ
04/06	Plus Therapeutics Announces CAP Accreditation of CNSide® Diagnostics Clinical Laboratory	AQ
26/05	Plus' CNSide Diagnostic Platform Demonstrates Substantial Healthcare Cost Reduction in Patients with Leptomeningeal Metastases	AQ
19/05	Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology	AQ
15/05	Plus: Q1 Earnings Snapshot	AQ